| Gabriel M Garber, MD | |
|
190 E Bannock St, Boise, ID 83712 | |
| (208) 381-2222 | |
| Not Available |
| Full Name | Gabriel M Garber |
|---|---|
| Gender | Male |
| Speciality | Hospitalist |
| Experience | 23 Years |
| Location | 190 E Bannock St, Boise, Idaho |
| Accepts Medicare Assignments | Yes. He accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1588632830 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 208M00000X | Hospitalist | MD188881 (Oregon) | Secondary |
| 207R00000X | Internal Medicine | M9555 (Idaho) | Primary |
| Facility Name | Location | Facility Type |
|---|---|---|
| Saint Alphonsus Regional Medical Center | Boise, ID | Hospital |
| Saint Alphonsus Medical Center - Ontario, Inc | Ontario, OR | Hospital |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| Saint Alphonsus Regional Medical Center Inc | 3476462359 | 509 |
News Archive
Chronic kidney disease (CKD) affects at least one in four Americans who are older than 60 and can significantly shorten lifespan. Yet the few available drugs for CKD can only modestly delay the disease's progress towards kidney failure. Now, however, a team led by researchers at the Perelman School of Medicine at the University of Pennsylvania, has found an aspect of CKD's development that points to a promising new therapeutic strategy.
When a person has a family history of cancer, their worry about developing the disease may lead to them refusing to have preventive tests. Advice from genetic counselling units reduces their anxiety but, until now, nobody knew how much. Now, a scientific team has validated the 'Escala de Preocupaci-n por el C-ncer - EPC' (equivalent of the Cancer Worry Scale), the first of its kind in the Spanish language, in order to evaluate it.
The Food and Drug Administration (FDA) today announced the formation of a multidisciplinary FDA task force on human cell and tissue safety.
Regeneron Pharmaceuticals, Inc. announced that in a second Phase 3 study (PRE-SURGE 2) in gout patients initiating allopurinol therapy, ARCALYST (rilonacept) met the primary and all secondary study endpoints. The primary endpoint was the number of gout flares per patient over the 16-week treatment period.
Six months after monsoon flooding hit Pakistan, the U.N. reports that about 4 million people remain without temporary or permanent shelter, VOA News reports.
› Verified 1 days ago
| Entity Name | Saint Alphonsus Regional Medical Center Inc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1649357716 PECOS PAC ID: 3476462359 Enrollment ID: O20040204001036 |
News Archive
Chronic kidney disease (CKD) affects at least one in four Americans who are older than 60 and can significantly shorten lifespan. Yet the few available drugs for CKD can only modestly delay the disease's progress towards kidney failure. Now, however, a team led by researchers at the Perelman School of Medicine at the University of Pennsylvania, has found an aspect of CKD's development that points to a promising new therapeutic strategy.
When a person has a family history of cancer, their worry about developing the disease may lead to them refusing to have preventive tests. Advice from genetic counselling units reduces their anxiety but, until now, nobody knew how much. Now, a scientific team has validated the 'Escala de Preocupaci-n por el C-ncer - EPC' (equivalent of the Cancer Worry Scale), the first of its kind in the Spanish language, in order to evaluate it.
The Food and Drug Administration (FDA) today announced the formation of a multidisciplinary FDA task force on human cell and tissue safety.
Regeneron Pharmaceuticals, Inc. announced that in a second Phase 3 study (PRE-SURGE 2) in gout patients initiating allopurinol therapy, ARCALYST (rilonacept) met the primary and all secondary study endpoints. The primary endpoint was the number of gout flares per patient over the 16-week treatment period.
Six months after monsoon flooding hit Pakistan, the U.N. reports that about 4 million people remain without temporary or permanent shelter, VOA News reports.
› Verified 1 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Gabriel M Garber, MD 190 E Bannock St, Boise, ID 83712-6241 Ph: (208) 381-2222 | Gabriel M Garber, MD 190 E Bannock St, Boise, ID 83712 Ph: (208) 381-2222 |
News Archive
Chronic kidney disease (CKD) affects at least one in four Americans who are older than 60 and can significantly shorten lifespan. Yet the few available drugs for CKD can only modestly delay the disease's progress towards kidney failure. Now, however, a team led by researchers at the Perelman School of Medicine at the University of Pennsylvania, has found an aspect of CKD's development that points to a promising new therapeutic strategy.
When a person has a family history of cancer, their worry about developing the disease may lead to them refusing to have preventive tests. Advice from genetic counselling units reduces their anxiety but, until now, nobody knew how much. Now, a scientific team has validated the 'Escala de Preocupaci-n por el C-ncer - EPC' (equivalent of the Cancer Worry Scale), the first of its kind in the Spanish language, in order to evaluate it.
The Food and Drug Administration (FDA) today announced the formation of a multidisciplinary FDA task force on human cell and tissue safety.
Regeneron Pharmaceuticals, Inc. announced that in a second Phase 3 study (PRE-SURGE 2) in gout patients initiating allopurinol therapy, ARCALYST (rilonacept) met the primary and all secondary study endpoints. The primary endpoint was the number of gout flares per patient over the 16-week treatment period.
Six months after monsoon flooding hit Pakistan, the U.N. reports that about 4 million people remain without temporary or permanent shelter, VOA News reports.
› Verified 1 days ago
Dr. Jennifer A Hofstra, MD Internal Medicine Medicare: Accepting Medicare Assignments Practice Location: 1055 N Curtis Road, Boise, ID 83706 Phone: 757-446-8920 Fax: 757-446-5242 | |
Dr. James Robert Polk, MD Internal Medicine Medicare: Not Enrolled in Medicare Practice Location: 1055 N Curtis Rd, Boise, ID 83706 Phone: 208-367-3104 | |
Dr. Michael Frederic Krug, M.D. Internal Medicine Medicare: Medicare Enrolled Practice Location: 500 W. Fort St, # 111, Boise, ID 83702 Phone: 208-422-1000 Fax: 208-422-1319 | |
Derrel V Walker, M.D. Internal Medicine Medicare: Medicare Enrolled Practice Location: 1055 N Curtis Road, Boise, ID 83706 Phone: 208-367-7350 Fax: 208-367-3951 | |
Dr. Janat E. O'donnell, MD Internal Medicine Medicare: Medicare Enrolled Practice Location: 500 W. Fort St., # 111, Boise, ID 83702 Phone: 208-422-1325 Fax: 208-422-1319 | |
Carl L Durning, MD Internal Medicine Medicare: Not Enrolled in Medicare Practice Location: 6094 W Emerald St, Boise, ID 83704 Phone: 208-367-6575 Fax: 208-367-6597 | |
Dr. Christopher J Goulet, M.D. Internal Medicine Medicare: Accepting Medicare Assignments Practice Location: 6259 W Emerald St, Boise, ID 83704 Phone: 208-489-1900 Fax: 208-375-5286 |